Thomas Brott, M.D.
Dr. Brott graduated from Harvard College and the University of Chicago Pritzker School of Medicine. He completed medical and neurological training at the Harvard Longwood Neurology Program (Beth Israel, Children’s and Peter Bent Brigham Hospitals) in Boston at the University of Cincinnati in 1981.
His first studies were of carotid surgery and intracerebral hemorrhage in the Greater Cincinnati / Northern Kentucky metropolitan area. He was the principal designer of the National Institutes of Health Stroke Scale (NIH SS). He held the original IND to study tPA as an acute treatment for ischemic stroke and was the principal investigator for the University of Cincinnati in the NINDS tPA Stroke Trial. With colleagues from the University of Cincinnati Stroke Team, Dr. Brott defined the evolution of spontaneous intracerebral hemorrhage during the first hours after onset. In 1998, Dr. Brott moved to Mayo Clinic in Jacksonville where James Meschia, John Hardy, and Dr. Brott initiated the first NIH-funded genome-wide screen for stroke susceptibility. Currently, he is Professor of Neurology, Mayo Clinic, national Co-Principal Investigator for the Carotid Revascularization Endarterectomy vs. Stent Trial (CREST), Co-Principal Investigator in the Siblings with Ischemic Stroke Study (SWISS), Co-Principal investigator in the Ischemic Stroke Genetics Study (ISGS), and principal neurologist in the Combination approach to Lysis utilizing Eptifibatide and r-tPA (CLEAR), all funded by NIH.